dc.contributor.author | McGettigan, P | |
dc.contributor.author | Olsen, A-MS | |
dc.date.accessioned | 2018-03-27T12:06:47Z | |
dc.date.available | 2018-03-27T12:06:47Z | |
dc.date.issued | 2017-06-17 | |
dc.date.submitted | 2017-10-11T22:18:14.396Z | |
dc.identifier.citation | McGettigan, P. and A.-M. S. Olsen "NSAIDs for high-risk patients: none, celecoxib, or naproxen?" The Lancet 389(10087): 2351-2352. https://doi.org/10.1016/S0140-6736(17)30980-7 | en_US |
dc.identifier.issn | 0140-6736 | |
dc.identifier.other | 10.1016/S0140-6736(17)30980-7 | |
dc.identifier.uri | http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(17)30980-7.pdf | |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/36105 | |
dc.description.abstract | Godot-like, the all-round safe and effective oral anti-inflammatory drug is awaited. Meantime, substantial effort is devoted to discovering how the existing imperfect non-steroidal anti-inflammatory drugs (NSAIDs) might be best used—balancing the need for effective analgesia with their multiple risks. The randomised controlled trial by Francis Chan and colleagues1 reported in The Lancet investigated two of these NSAIDs that have been seen as the best (or least worst) in the cardiovascular safety stakes, celecoxib and naproxen. | en_US |
dc.format.extent | 2351 - 2352 | |
dc.language.iso | en | en_US |
dc.publisher | Elsevier/Science Direct | en_US |
dc.relation.ispartof | LANCET | |
dc.rights | All rights reserved. | |
dc.subject | NSAIDs | en_US |
dc.subject | anti-inflammatory drugs | en_US |
dc.subject | analgesia | en_US |
dc.title | NSAIDs for high-risk patients: none, celecoxib, or naproxen? | en_US |
dc.type | Article | en_US |
dc.rights.holder | 2017. Elsevier | |
dc.identifier.doi | 10.1016/S0140-6736(17)30981-9 | |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000403334400007&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | |
pubs.declined | 2017-10-11T22:18:13.950+0100 | |
pubs.issue | 10087 | |
pubs.publication-status | Published | |
pubs.volume | 389 | |